deltatrials
Recruiting NA INTERVENTIONAL 1-arm NCT06291896

A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection

A Multicentric, Prospective Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection to Make Breast Cancer Screening More Accurate, Inclusive, and Female-friendly

Sponsor: ELAROS 24/7 Limited (UK)

Interventions MammoWave
Updated 6 times since 2024 Last updated: Jan 3, 2025 Started: Mar 15, 2024 Primary completion: Feb 15, 2026 Completion: Dec 15, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06291896, this NA trial focuses on Women's Health: Neoplasm of Breast and remains actively recruiting participants. Sponsored by ELAROS 24/7 Limited (UK), it has been updated 6 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshotRecruiting~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshotRecruiting~Sep 2025 – present · 10 months · monthly snapshotRecruiting

Change History

6 versions recorded
  1. Sep 2025 — Present [monthly]

    Recruiting NA

  2. Feb 2025 — Sep 2025 [monthly]

    Recruiting NA

  3. Sep 2024 — Feb 2025 [monthly]

    Recruiting NA

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting NA

  5. Jun 2024 — Jul 2024 [monthly]

    Recruiting NA

Show 1 earlier version
  1. Apr 2024 — Jun 2024 [monthly]

    Recruiting NA

    First recorded

Mar 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ELAROS 24/7 Limited (UK)
  • EVITA - Cancro Hereditário (Portugal)
  • Fondazione Toscana Life Sciences (Italy)
  • IMT School for Advanced Studies Lucca
  • London South Bank University
  • Servicio De Salud De Castilla La Mancha (Spain)
  • Umbria Bioengineering Technologies
Data source: Umbria Bioengineering Technologies

For direct contact, visit the study record on ClinicalTrials.gov .